G-CSF Endogenous G-CSF Response to Infection
The glycoprotein G-CSF is present at low concentrations (around 25 pg/ml) in the serum of healthy volunteers.
1 A significant increase in G-CSF secretion may be detected during the acute phase of a bacterial infection.4--6 Patients may have peak concentrations as high as 200 ng/ml at the onset of septic shock. 7 These levels decrease significantly within a few days in survivors, but in nonsurviving sepsis patients the G-CSF levels remain persistently elevated.B,g Furthermore, patients who do not respond to infection with increased G-CSF production have a worse prognosis than patients who respond with G-CSF production. 10 These studies showed that patients with the best outcome are those who are able to respond appropriately to an infectious agent by increasing G-CSF levels and then decreasing them upon resolution of the infection. However, in patients with a fatal outcome, G-CSF levels tend to remain elevated, indicating an inability of the host to respond to circulating G-CSF, continued signaling for G-CSF production, or failure of the host to mount a sufficient G-CSF response. 11 The observation that i~ection of pharmacologic doses of G-CSF (10 Ilg/kg) into healthy volunteers elevated the serum G-CSF to levels in the upper range of those reached by endogenous production during infection 12 supports the hypothesis that administration of G-CSF under the conditions discussed above may be beneficial to the host by increasing or accelerating the response to infection.
Role of G-CSF in the Cellular Immune System
The central role of endogenous G-CSF lies in the maintenance and control of granulopoiesis, which is essential for efficient host defense, as demonstrated in knockout mice. 13 or in normal mice i~ected with anti-murine G-CSF antiserum. 14 Effects of G-CSF on the Humoral Response lasting throughout the whole 12 days of treatment with G-CSF (filgrastim). Counts equal to those prior to treatment were seen 72 hour after the I~st injection, (unpublished observation, submitted for publication). Lesser increases in monocyte and lumphocyte counts have also been reported. 16 In addition to increasing the pool of circulating neutrophils, G-CSF primes these immune cells for enhanced effector functions by improving the oxidative burst, phagocytosis, and chemotaxis and by extending their lifetime by delaying apoptosis. I 7-19 Thus G-CSF promotes the migration of increasing numbers of immunocompetent and higWy potent neutrophils to the focus of infection in an effort to eradicate invading microbes. Neutrophils pose the first line of defense against all particles identified as foreign; but they may cause damage to host tissues if they are activated prematurely or damaged or if the inflammatory reaction is not terminated on time. 20 Thus during the exploration of possible indications for G-CSF, it was necessary to consider whether the newly recruited neutrophils were functional or preactivated and whether application of G-CSF might unbalance the cytokine mediator network, resulting in exacerbation of the inflammatory reaction. The in vitro studies discussed above showed that G-CSF does not directly activate but, rather, primes PMNs for increased responsiveness to subsequent stimulation. The implication of this priming effect of G-CSF on PMNs is that their functions are potentiated only in the case of stimulation by exogenous signals.
Granulocyte colony-stimulating factor Colony-stimulating factor Por 3, respectively Macrophage/granulocyte inducer lG or 2, respectively Granulocyte/ macrophage colony-stimulating acti\~ty Differentiation factor; pluripoietin Pluripotent colony-stimulating factor Granulocyte/ macrophage colony-stimulating factor Colony-stimulating factor a or 2, respectively Macrophage/granulocyte inducer lGM Eosinophil colony-stimulating factor Hematopoietic cell growth factor Keratinocyte-derived T cell growth factor T cell-derived neutrophil migration inhibition factor Synonym Abbreviation neutrophils from the bone marrow in response to an infectious challenge and were therefore more susceptible than controls to sublethal doses of infeetive agents.
Doses of G-CSF ranging from I to 60 fIg/kgl day given to human volunteers for 6 days produced dose-dependent 1.8-to 12-fold increases in the absolute neutrophil count. 15 In a volunteer study, we found a dose-dependent increase of the polymorphonuclear neutrophil (PMN) count with a plateau
The inflammatory response is driven primarily by the cytokincs tumour necrosis fa~or-IX (fNFIX), interleukin-l (IL-l), and interferon-y (lFNy), which are produced by monocytes/macrophag-es and lymphocytes. Endogenous countermeasures include-a reduction in their production or secretion and the release of their respective antagonists: soluble TNF receptors (sTNF-R) or IL-I receptor antagonist (IL-I raj.
In vitro and ex vivo experiments indicated that G-CSF adjusts the response of rodent and human mononuclear cells to immunostimulatory agents, such as the gram-negative cell wall Neutrophils from these G-CSF-treated volunteers showed increased ex vivo LPS-inducible IL-lra release, whereas the shedding of soluble TNF receptors was unaffected when calculated per PMN, though of course these cells were present in significantly higher numbers in the blood of the G-CSF-treated subjects. 25 Furthermore, the release capacity of the chemoattractive leukotriene B 4 , when expressed per neutrophil, was decreased significantly. This finding can be interpreted as a further antiinftammatory effect of G-CSF unrelated to the cytokine network (unpublished observations), In addition, IFNy formation by Iymphocytes was attenuated in whole blood incubated in the presence of LPS. Thus the overall antiinflammatory effect of a single G-CSF il1jection consisted of the attenuated release of proinflammatory mediators by monocytes and lymphocytes and concomitant augn1ented formation and secretion of the respectivc antagonists by neutrophils.
In another study we examined the effects of daily G-CSF treatment for 12 days in 24 healthy volunteers. Compared to a placebo group, TNFa, IL-12, and IFNy release in whole blood samples in response to ex vivo stimulation by LPS was reduced in the verum groups compared with the control group throughout treatment. Thus the antiinftammatory effect of G-CSF is also maintained under sustained treatment regimens. The in vitro addition of IL-12 to LPS-stimulated blood lcssened the attenuation of IFNI' and TNFIi release capacity, indicating that suppression of IL-12 release in pivotal is the antiinftammatory activity to G-CSF.
To assess the time \vindow during which treatment with exogenous G-CSF might improve the coursc of an infection, a volunteer trial was held in which G-CSF was injected 2 or 24 hours before challenge with LPS in vivo. 26 Administration of G-CSF shortly before LPS boosted the levels of TNF, IL-6, IL-8, IL-lra, and both kinds ofsTNF-R. In comparison, G-CSF injection I day prior to challenge significantly decreased IL-8 levels and moderately attenuated the release of TNF and IL-6. The release of 11.-1 ra and sTNF-R had increased prior to LPS injection. Administration of LPS resulted in a further increase in the sTNF-R I and II levels, whereas IL-l ra release remained unaltered. Despite the different effects on cytokine release patterns, the two treatment regimens resulted in similar positive effects on neutrophil activation and similar changes in surface molecule expression. Moreover, both G-CSF pretreatments blocked LPS-induced granulocyte accumulation in the lung.
G-CSF in Sepsis Models
Many studies have been performed in diverse animal models to explore the relevance of these observations during sepsis and 623 septic shock and to determine whether unacceptable side effects are associated with G-CSF treatment of these conditions. The efficacy of G-CSF, alone or in combination with antibiotics, has been explored in a wide variety of nonneutropenic infectious disease models ineluding neonatal sepsis, pneumonia, infections complicated by ethanol intoxication, burn wound infection, intraabdominal sepsis, and intramuscular infection. 18 ,27 Results from these studies and those discussed below, in which the survival rate was increased significantly by G-CSF in most cases, indicated that prophylactic administration of G-CSF as a pretreatment when an increased risk of infection is foreseeable, (e.g., before an operation) may be beneficial prophylactically.
In all the animal studies discussed below, G-CSF treatment was initiated prior to or simultaneous with the infectious challenge. Results pertaining to the activity of neutrophils under G-CSF treatment in defense against infection were mostly uniformly positive: recruitment of neutrophils to the site of infection was improved in a pneumonia model 28 and infections seemed to remain more localized in infections with Escherichia coli, through cecal ligation and puncture (CLP) or with subcutaneous injections, than in control animals 29 ,3o as detem1inedby histological evidence, myeloperoxidase activity, or glucose uptake in tissue adjacent to the site of infection. However, in a murine model where radionuclide-labeled E. coli were injected, no differences in the translocation through tissues were observed. 31 However, improved bactericidal activity was reported in each of these cases and in models of pneumonia and . " 3233 pentomus. ' Regarding cytokine levels during infection, TNFlX serum levels in G-CSF-treated animals were reported to be decreased compared to levels in controls in infection models in mice, rats and
ogs. . --treate g actosamme-sensluze mice exhibited reduced IL-2 serum levels without an effect on TNFa release. 37 Rabbits with immune complex colitis had lower levels of the proinftammatory leukotriene B 4 and thromboxane B 2 , but levels of the antiinftammatory prostaglandin £2 were not affected. 38 Apart from the general improvement in the course and outcome of infections, there is evidence that prophylactic treatment with G-CSF would be beneficial in the specific treatment of septic shock. G-CSF was shown to protect
d h k 2139 ro ents agamst en otoxm-m uce epatotoXlclty an s oc ' and peritonitis-induced multiple organ failure and death. 6 ,4-0 It also improved cardiovascular function, endotoxin clearance, and survival in two canine models of septic shock. 6, 41 Neutrophils have been implicated as key mediators in the pathogenesis of acute lung injury due to sepsis or endotoxemia. Accordingly, deliberate augmentation of neutrophil production and activity might be deleterious in patients with sepsis. Several studies have addressed this issue by examining the effects of G-CSF treatment on acute lung injury in guinea pigs,42 pigs,29,43 and sheep44 challenged with LPS. The data from these preclinical studies have been consistent in showing no evidence of exacerbation of lung injury as a consequence of treatment with G-CSF.
Use of G-CSF in Clinical Trials
The benefits of G-CSF treatment in nonneutropenic animal models of infection provided a basis for clinical studies on the effects of G-CSF in regard to the incidence and course of infections that might result in sepsis. G-CSF proved to be safe in intensive care unit (lCV) and septic patients,IO,4-5,4-6 who apparently also benefited from the therapy. Generation and function of neutrophils was improved in 20 postoperativeI posttraumatic patients at risk of sepsis or with sepsis who were given continuous infusions of G-CSF (filgrastim) for 7 days. Furthennore, IL-8 decreased in all six patients whose initial IL-8 values were >90 pg/ml. IL-Ira increased in 10 patients, though there was no effect on the levels of TNFex or sTNF-R type 1.4-7
When G-CSF treatment was commenced before an operation it significantly reduced the incidence of infectious complications in 19 cancer patients undergoing esophagectomy compared with 77 control patients. 7 G-CSF reduced the incidence of multiple organ failure in 756 pneumonia patients 4-8 and 37 liver all fi ..
4-9 ogra t reCipients.
In conclusion, G-CSF showed antiinflammatory effects combined with improved host defense, not only in preclinical models but also in the clinical setting. Previous clinical experience has shown that the use of G-CSF is associated with a very low incidence of side effects, except mild bone pain. Therefore further trials of G-CSF given for prophylaxis of sepsis and septic complications are ratified, and \Nidespread use of G-CSF in this setting might be considered a clinical option in the near future.
GM-CSF
The initial phase of the systemic inflammatory response syndrome (SIRS) is characterized by excessive production of proinflammatory cytokines by monocytesl macrophages and is therefore termed the hyperinflammatory phase. 50 Here, antiinflammatory therapy (e.g., anti-TNF antibodies, IL-lra, IL-IO) was proposed as the appropriate measure. 5I However, it has been found that this initial phase is followed by a so-called hypoinflammatory phase, also tenned immune paralysis. 52 ,53 Many patients who survive the acute hyperinflammation owing to intensive medical care succumb to subsequent infections. In such patients a drastic change in monocyte activity was observed (i.e., in vitro): The monocytes are no longer able to respond to an inflammatory stimulus such as LPS with secretion of proinflammatory cytokines (e.g., TNFex).52,54-59 The longer this state of immune paralysis continues, the more adverse is the . 52 56
econ ary 111 ectlOns unng t e con loon 0 immune paralysis (i.e., when the organism's state of defense is insufficient) often detennine the fate of a patient during septic multiple organ failure.
Therefore a therapeutic goal consists in the reconstitution of immune competence during the late phase of septic shock. For such an indication, immune stimulation with GM-CSF seems to represent a promising pharmacologic therapeutic principle. GM-CSF is a pluripotent hematopoietic growth factor involved in regulating the proliferation, differentiation, and mature functions of granulocytes and monocytlCs,' macrophages,60 the two key cell types of the nonspecific immune system. GM-CSF has been used to accelerate recovery of the granulocyte and monocyte counts after chemotherapy or bone marrow transplantation, thereby reducing the risk of infections from bacterial or fungal sources due to leukope-. 61-64-rna.
Role of Endogenous GM-CSF
The role of GM-CSF in vivo became evident in knockout animals. Mice with homozygous mutations of the GM-CSF gene showed no major deficits in hematopoiesis until 12 weeks of age, but they developed abnonnal lungs and some suffered from subclinical bacterial or fungal infection. 65 These observations indicate that GM-CSF is not essential for maintenance of hematopoietic cells and their precursors but, rather, for nonnal pulmonary physiology and resistance to local inrection. This conclusion was supported by the finding that the administration of neutralizing monoclonal antibodies specific for GM-CSF to Cryptococcus ne!!jimnans-infected nonnal mice increased mortality and induced rapid progresssion of the disease. 66 To explore further the in vivo role of GM-CSF in infection, GM-CSF knockout mice were treated with endotoxin (LPS). Hypothennia and loss of body weight were markedly attenuated in LPS-treated GM-CSF-deficient mice compared with similarly treated control mice. Moreover, the levels of the circulating proinflammatory cytokines IFNy, ILl ex, and IL-6 were lower in LPS-treated GM-CSF-deficient mice than in LPS-treated control mice. Peak levels of TNFex in response to LPS treatment were the same in the serum of all the mice, but TNFex persisted longer in GM-CSF-deficient mice. LPS-stimulated peritoneal macrophages from GM-CSF-deficient mice produced significantly less IL-I ex and nitric oxide than macrophages from wild-type mice, although there was no difference in TNFex production in vitro. These results indicate that GM-CSF contributes to cytokine production in LPS-mediated septic shock and that the attenuated production of these secondary cytokines (lFNy, IL-Iex, and IL-6) may contribute to the endotoxinresistant phenotype of GM-CSF-deficient mice. 67 
GM-CSF as an Immunostimulatory Drug
The initiation of host defense in the fonn of an inflammatory reaction is mediated primarily by the cytokines TNFex and IL_1. 68 -7 4-GM-CSF was found to potentiate LPS-induced TNFex and IL-I production of murine and human monocytic cells. 58 ,75-n We also found that GM-CSF is a potent enhancer of LPS-induced TNFex production in vivo in nonnal and experimentally immunocompromised (LPS-desensitized) mice. 78 Furthennore, in vitro and ex vivo experiments revealed that LPS-induced IL-I release from bone marrow or spleen cells was also enhanced in GM-CSF-treated mice. 107 GM-CSF Production: Strictly Controlled GM-CSF is not detectable in the circulation of healthy animals or humans, though it may be found in the major organs at low concentrations.
79 Only small amounts of GM-CSF were measured in the serum of mice infected with Listeria monocytogenes.
. c: 82 attents WIt 1 expenment en otoxemla, neutropemc lever, or even sepsis 83 also do not normally have elevated serum GM-CSF levels. In patients with meningococcemia GM-CSF concentrations higher than I ng/ml were only briefly present in subjects ,.vith life-threatening septic shock and were strongly associated with fulminant infection. 6 As no systemic GM-CSF levels can be detected in patients with infection, endogenous GM-CSF is thought to play its physiologic role in the immediate vicinity of the cells by which it is secreted. 84 ,85 The hypothesis is supported by the observation that in patients with meningitis only cerebrospinal fluid contained a measurable concentration of GM_CSF. 86 In summary, it appears that the body highly restricts production of the powerful immunostimulator GM-CSF. Therefore it is not surprising that rats who underwent CLP with sepsis-induced organ injury, when given rmGM-CSF, showed no increased survival rates but, rather, earlier deaths than the control group. Early leukosequestration to the peritoneal cavity was inhibited, and severe liver injuries were observed,87 that might have resulted from the stimulating activity ofGM-CSF on the expression ofTNF. One study found that survival in two mouse models of gut-derived sepsis was improved by pretreatment with GM-CSF because of better gut barrier function and better bacterial clearance. 88 However, we found that prophylactic administration of rmGM-CSF neither augmented leukocyte numbers nor protected mice from lethal fecal peritonitis.
14 Consequently, systemic application of GM-CSF may be detrimental if given before or during the proinflammatory phase of sepsis. 108 
GM-CSF in Models of Impaired Immune Competence
A number of studies have been performed in which neonatal rats (which are more vulnerable to infection than older animals) or animals first made susceptible to infection by trauma, bum, or myelosuppression were treated with exogenous GM-CSF and subsequently challenged by CLP or inoculation of infective agents. These studies may be considered models for the diminished status of the immune system experienced at the hypoinflammatory stage of sepsis. Neonatal rats were found to have deficient PMN production and function during infection. Prophylactic rmGM-CSF given intraperitoneally 6 hours before a 90% lethal dose challenge with Stapl!J!lococcus aureus significantly improved survival in a neonatal rat model of infection. 89 In another study, neonatal rats with streptococcal sepsis were given rhGM-CSF after infection. A higher survival rate than in control animals not given rhGM-CSF was reported, apparently due to phagocyte priming or cellular influx into the peritoneum (or both),9o even though human GM-CSF is generally believed not to be bioactive in mice. Furthermore, GM-CSF administered in conjunction with penicillin to neonatal rats with established group B streptococcal infection decreased the mortality rate substantially in comparison to penicillin alone. 91
Mice made susceptible to infection by trauma wert reated with GM-CSF for 5 days before induction of peritonitis. These mice had a significantly higher survival rate than control mice, which underwent the same regimen but received placebo instead of GM-CSF. Peritoneal cell yields were increased in the GM-CSF group, and harvested macrophages stimulated with phorbol ester released larger amounts of both superoxide anion and TNF and less nitric oxide than mice in 92 the control group.
In a murine model 20% surface burns plus CLP were applied. Survival was significantly better on day 10 after injury in aninlals treated with GM-CSF on days 5-9 after the burn. 93 Concanavalin A-stimulated T cell proliferation and IL-2 production, which were suppressed after bum injury, were also improved by treatment with GM_CSF. 93 The infection of GM-CSF-pretreated, myelosuppressed mice with normally lethal doses of Pseudomonas aeruginosa, Staphylococcus aureus, or Candida albicans resulted in a sigrIificant dose-dependent improvement of survival. 94 ,95 There has also been research on combinations of GM-CSF with IL-6 or leukemia inhibitory factor (LIF), which are both potent inducers of the acute-phase response and can induce an increase in the platelet count. 95 The rationale for these combinations was that the synergism of the induction of opsonization of microorganisms by acute-phase proteins with activation of phagocytes by GM-CSF should increase resistance to infections. This hypothesis was proven correct when myelosuppressed mice were treated with either of the combinations and infected with Pseudomonas aeruginosa. 96 Preclinical studies with recombinant human GM-CSF are limited by the lack of cross-species reactivity in mice. 97
The protein sequence homology between human and murine GM-CSF is only 60%.98 Human GM-CSF does not affect canine PMNs in vitro;99 and even in monkeys only-short-term studies can be undertaken because antibodies develop to human GM-CSF. 62 However, because of the dangers associated with immune stimulation, volunteer studies may be considered unethical. We have taken advantage of a dose-finding study of GM-CSF for wound healing of basalioma, where we investigated the change in white blood cell count and the cytokine production pattern ex vivo in blood from patients treated with low doses ofGM-CSF. Patients responded to the treatment with a general leukocytosis, though only the eosinophil fraction was significantly increased relative to the other populations. Cytokine secretion from GM-CSFtreated patients in response to either LPS or Jipoteichoic acid was characterized by decreased IFN)' and increased IL-1O and IL-Ira secretion and can therefore basically be considered an antiinflammatory reaction. Side effects were also relatively mild (unpublished observation; submitted for publication).
These results indicate that leukocytosis can be initiated by low doses of GM-CSF, with which the proinflammatory priming, observed in vitro and in animal models at higher doses, is replaced by a trend toward an antiinflammatory cytokine pattern.
Potential Application of GM-CSF for Human Sepsis
Although monocytes from septic shock patients exhibit greater baseline respiratory burst activity than monocytes from healthy subjects, the response to secondary stimulation with bacterial stimuli is attenuated. 100 GM-CSF restored the ability of monocytes to respond appropriately to secondary stimulation. Expression of certain integrin adhesion molecules, CD62L, and Fcy receptors was increased on monocytes of septic shock patients; expression of CDllc was reduced. GM-CSF upregulated integrin expression and decreased CD62L, CD32, and CD 16 expression. Priming monocytes with GM-CSF accelerated tissue factor activation following stimulation with LPS and resulted in a significant increase of in vivo plasma levels of IL-I ra and a trend toward increased IL-8 levels in cancer patients. 102 A case has been reported where a patient in the ICU with acquired agranulocytosis and sepsis experienced rapid neutrophil recovery and resolution of a clinical infection when treated with GM_CSF. 103
Possible Adverse Effects
In humans, systemic administration of GM-CSF at doses sufficient to produce plasma levels comparable to endogenous levels seen during severe meningcoccal septic shock induced vasodilatation, hypotension, and hypoxia. 6 In a model where GM-CSF was highly expressed in rat lung after intrapulmonary transfer of the gene coding for murine GM-CSF using an adenoviral vector, a sustained but self-limiting accumulation of eosinophils and macrophages was associated with tissue injury in the lung followed by varying degrees of irreversible fibrotic reactions observed at later stages, suggesting that GM-CSF plays a role in the development of respiratory conditions characterized by eosinophilia, granuloma, or fibrosis.l0 4 Increases in plasma GM-CSF in patients with inflammatory . h h 86 I . d . C • 105 disorders suc as ast ma or granu OCytOSIS ue to ImectlOn indicate that GM-CSF should be used with caution in patients with respiratory diseases. However, in a patient with T lymphocytosis with granulocytopenia and severe perianal infection, the eosinophilia initiated by GM-CSF (12.5 f.1g/kg fell' 8 days) correlated with improvement of the perianal ulceration. 106 T. Hartung, S. van Aulock, and A. Wendel Conclusions A number of studies have indicated that the immunostimulatorv properties of GM-CSF may be beneficial in reconstituting tht' compromised immune system, thereby improving the outcome after secondary infections or sepsis.
